Quotes 5-day view Delayed Nasdaq
10/16/2020
10/19/2020
10/20/2020
10/21/2020
10/22/2020
Date
280.01(c)
268.77(c)
267.12(c)
268.91(c)
266.8(c)
Last
843 290
1 207 981
1 156 111
1 848 881
1 266 743
Volume
-0.22% -4.01% -0.61% +0.67% -0.78% Change
Sales 2020
13 446 M - -
Net income 2020
4 465 M - -
Net Debt 2020
2 565 M - -
P/E ratio 2020
9,58x
Yield 2020
-
Sales 2021
11 574 M - -
Net income 2021
3 678 M - -
Net Debt 2021
132 M - -
P/E ratio 2021
10,4x
Yield 2021
-
Capitalization
41 380 M 41 380 M -
EV / Sales 2020
3,27x
EV / Sales 2021
3,59x
Nbr of Employees
7 400
Free-Float
86,4%
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (79.2%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (15.9%);
- other (4.9%): primarily revenues from partnership agreements.
Notations Surperformance© of Biogen Inc.
Trading Rating : Investor Rating :
All news about BIOGEN INC.
News in other languages on BIOGEN INC.
Special Report: Big Pharma wages stealth war on drug price watchdog
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends BIOGEN INC.
Short Term Mid-Term Long Term Trends Neutral Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
HOLD
Number of Analysts
33
Average target price
296,46 $
Last Close Price
268,91 $
Spread / Highest target
43,5%
Spread / Average Target
10,2%
Spread / Lowest Target
-15,2%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
